| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439435 | European Journal of Cancer | 2018 | 6 Pages |
Abstract
IDEA risk classification per se does not predict for treatment benefit from doublet chemotherapy in stage III colon cancer. However, omission of oxaliplatin can be considered in IDEA low-risk patients older than 72 years.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ofer Margalit, Ronac Mamtani, Yu-Xiao Yang, Kim A. Reiss, Talia Golan, Naama Halpern, Dan Aderka, Bruce Giantonio, Einat Shacham-Shmueli, Ben Boursi,